Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xenovac
- Development stage
- Preclinical
- Lead developer
- Innovita Research
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
01
Overview
Xenovac is a xenogeneic cell-based vaccine developed by Innovita Research for the treatment of melanoma and various carcinomas. The vaccine is formulated with cellular material containing melanoma- and carcinoma-associated differentiation antigens. It is designed to overcome immune tolerance to weakly immunogenic homologous tumor-associated antigens by presenting them as 'altered self,' thereby inducing a robust, tumor-specific immune response to eliminate cancer cells.
Beyond the preview
Go deeper on Xenovac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xenovac.